473545-40-3

Usage

Uses

Used in Organic Synthesis:
Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1is used as a reagent in organic synthesis for the preparation of various chemical compounds.
Used in Pharmaceutical Manufacturing:
Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1is used as an intermediate in the production of pharmaceuticals, contributing to the development of new drugs.
Used in Medicinal Chemistry and Drug Development:
Carbamic acid, [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1is used in the field of medicinal chemistry and drug development due to its potential applications in creating new therapeutic agents.
Used in Pharmaceutical Industry Research and Development:
Carbamic acid derivatives, including [(1R)-2-hydroxy-1-(hydroxymethyl)-2-methylpropyl]-, 1,1-, are studied for their biological activities and pharmacological properties, making them important targets for research and development in the pharmaceutical industry.

Upstream product

• 864181-31-7 1-methyl-1-[(4R)-2-oxo-1,3-oxazolidin-4-yl]ethyl benzoate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 102507-13-1 N-(tert-butoxycarbonyl)-3-hydroxy-L-valine 
• 75-16-1 methylmagnesium bromide 
• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 
• 108149-60-6 methyl [(4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidin-4-yl]carboxylate 
• 288159-36-4 tert-butyl (4R)-4-(1-hydroxy-1-methylethyl)-2,2-dimethyl-1,3-oxazolidine-3-carboxylate 
• 126181-46-2 (2R)-methyl 2-((tert-butoxycarbonyl)amino)-3-((tetrahydro-2H-pyran-2-yl)oxy)propanoate 
• 95715-86-9 (S)-2,2-dimethyl-oxazolidine-3,4-dicarboxylic acid 3-tert-butyl ester 4-methyl ester 
• 556-82-1 3-methyl-2-buten-1-ol 
• 116347-29-6 [(2S)-3,3-dimethyloxiran-2-yl]methanol 
• 473452-22-1 methyl (S)-2-(tert-butoxycarbonylamino)-3-hydroxy-3-methylbutanoate 

Downstream Products

• 473452-26-5 (2S)-2-(N-t-butoxycarbonyl)amino-3-methyl-3-hydroxypropan-1-al 
• 269742-33-8 (2S)-2-(N-tert-Butoxycarbonyl)amino-3-methylbut-3-enoic acid 
• 102507-13-1 N-(tert-butoxycarbonyl)-3-hydroxy-L-valine 
• 1275621-77-6 methyl (S)-2-(2,4-dinitrophenylsulfonamido)-3-hydroxy-3-methylbutanoate 
• 1275621-78-7 methyl (S)-1-(2,4-dinitrophenylsulfonyl)-3,3-dimethylaziridine-2-carboxylate 
• 1275621-80-1 benzhydryl (S)-2-(tert-butoxycarbonylamino)-3-hydroxy-3-methylbutanoate 
• 1275621-81-2 (S)-1-(benzhydryloxy)-3-hydroxy-3-methyl-1-oxobutan-2-aminium chloride 
• 1275621-82-3 benzhydryl (S)-2-(2,4-dinitrophenylsulfonamido)-3-hydroxy-3-methylbutanoate 
• 1275621-83-4 benzhydryl (S)-1-(2,4-dinitrophenylsulfonyl)-3,3-dimethylaziridine-2-carboxylate 
• 1275621-84-5 benzhydryl (S)-3,3-dimethylaziridine-2-carboxylate 
• 59979-01-0 thiocillin I 
• 102507-19-7 (S)-tert-butyl 1-(benzyloxyamino)-3-hydroxy-3-methyl-1-oxobutan-2-ylcarbamate 
• 102507-25-5 (3S)-3-[(t-Butyloxycarbonyl)amino]-4,4-dimethyl-1-(phenylmethoxy)-2-azetidinone 
• 123176-14-7 C₁₆H₃₆N⁽¹⁺⁾*C₁₀H₁₇N₂O₇S^(1-) 

Relevant academic research and scientific papers

MONOBACTAM COMPOUNDS AND USE THEREFOR

Monobactam compounds and a use therefor. Specifically provided are chemical compounds represented by formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals, or prodrugs thereof, preparation methods therefor, pharmaceutical compositions containing said compounds, and a use of said compounds or compositions in treating bacterial infection. The present compounds feature excellent antibacterial activity, and have great hopes of becoming a therapeutic agent for bacterial infection.

Gold-Catalyzed Amide/Carbamate-Linked N, O-Acetal Formation with Bulky Amides and Alcohols

A gold-catalyzed N,O-acetal formation was established to construct an amide/carbamate-linked N,O-acetal substructure with bulky alcohols. The acyliminium cation species generated from o-alkynylbenzoic acid ester in the presence of a gold catalyst is highly reactive and underwent nucleophilic attack of various bulky alcohols and phenols at room temperature under neutral conditions, leading to the corresponding N,O-acetals in yields of 34-89% with good functional group tolerance.

APPLICATION OF MONOCYCLIC BETA-LACTAM COMPOUND IN PHARMACY

An application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in preparation of a drug for treating pneumonia.

N-1 BRANCHED ALKYL ETHER SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, COMPOSITIONS, AND METHODS

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N-1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

MONOCYCLIC B-LACTAM COMPOUND FOR TREATING BACTERIAL INFECTION

Disclosed are a class of new monocyclic β-lactam compounds, an isomer thereof or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the compounds, and the use of same in preparing drugs for treating diseases associated

Optimization of LpxC Inhibitors for Antibacterial Activity and Cardiovascular Safety

UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) is a Zn2+ deacetylase that is essential for the survival of most pathogenic Gram-negative bacteria. ACHN-975 (N-((S)-3-amino-1-(hydroxyamino)-3-methyl-1-oxobutan-2-yl)-4-(((1R,2R)-2-(hydroxymethyl)cyclopropyl)buta-1,3-diyn-1-yl)benzamide) was the first LpxC inhibitor to reach human clinical testing and was discovered to have a dose-limiting cardiovascular toxicity of transient hypotension without compensatory tachycardia. Herein we report the effort beyond ACHN-975 to discover LpxC inhibitors optimized for enzyme potency, antibacterial activity, pharmacokinetics, and cardiovascular safety. Based on its overall profile, compound 26 (LPXC-516, (S)-N-(2-(hydroxyamino)-1-(3-methoxy-1,1-dioxidothietan-3-yl)-2-oxoethyl)-4-(6-hydroxyhexa-1,3-diyn-1-yl)benzamide) was chosen for further development. A phosphate prodrug of 26 was developed that provided a solubility of >30 mg mL?1 for parenteral administration and conversion into the active drug with a t1/2 of approximately two minutes. Unexpectedly, and despite our optimization efforts, the prodrug of 26 still possesses a therapeutic window insufficient to support further clinical development.

A motif-Oriented Total Synthesis of Nannocystin Ax. Preparation and Biological Assessment of Analogues

The highly cytotoxic cyclodepsipeptides of the nannocystin family are known to bind to the eukaryotic translation elongation factor 1α (EF-1α). Analysis of the docking pose, as proposed by a previous in silico study, suggested that the trisubstituted alkene moiety and the neighboring methyl ether form a domain that might be closely correlated with biological activity. This hypothesis sponsored a synthetic campaign which was designed to be motif-oriented : specifically, a sequence of ring closing alkyne metathesis (RCAM) followed by hydroxy-directed trans-hydrostannation of the resulting cycloalkyne was conceived, which allowed this potentially anchoring substructure to be systematically addressed at a late stage. This inherently flexible approach opened access to nannocystin Ax (1) itself as well as to 10 non-natural analogues. While the biological data confirmed the remarkable potency of this class of compounds and showed that the domain in question is indeed an innate part of the pharmacophore, the specific structure/activity relationships can only partly be reconciled with the original in silico docking study; therefore, we conclude that this model needs to be carefully revisited.

AMIDINE SUBSTITUTED BETA - LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS

The present invention relates to novel β-lactam compounds of formula (I), their preparation and use. In particular, this invention relates to novel β-lactam compounds which are amidine substituted monobactam derivatives useful as antimicrobial agents and their preparation.

Proof of the existence of an unstable amino acid: Pleurocybellaziridine in pleurocybella porrigens

Angel's wing mushroom, Pleurocybella porrigens, caused fatal acute encephalopathy in Japan in 2004. The structures of cytotoxic amino acids previously isolated from the mushroom motivated a study to prove the existence of an aziridine amino acid, pleurocy

Total synthesis and complete structural assignment of thiocillin i

The total synthesis of the thiopeptide antibiotic, thiocillin I, is described. This work unequivocally defines the full structure (constitution and configuration) of the natural product as 1.